Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Accumulated Expenses (2023 - 2025)

Historic Accumulated Expenses for Beta Bionics (BBNX) over the last 3 years, with Q3 2025 value amounting to $17.6 million.

  • Beta Bionics' Accumulated Expenses changed N/A to $17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.6 million, marking a year-over-year change of. This contributed to the annual value of $15.8 million for FY2024, which is 9473.43% up from last year.
  • Latest data reveals that Beta Bionics reported Accumulated Expenses of $17.6 million as of Q3 2025.
  • Beta Bionics' Accumulated Expenses' 5-year high stood at $17.6 million during Q3 2025, with a 5-year trough of $8.1 million in Q4 2023.
  • Its 3-year average for Accumulated Expenses is $13.1 million, with a median of $13.4 million in 2025.
  • Examining YoY changes over the last 5 years, Beta Bionics' Accumulated Expenses showed a top increase of 9473.43% in 2024 and a maximum decrease of 9473.43% in 2024.
  • Quarter analysis of 3 years shows Beta Bionics' Accumulated Expenses stood at $8.1 million in 2023, then surged by 94.73% to $15.8 million in 2024, then increased by 11.23% to $17.6 million in 2025.
  • Its Accumulated Expenses stands at $17.6 million for Q3 2025, versus $13.4 million for Q2 2025 and $10.6 million for Q1 2025.